@floriansimon.bsky.social
Physician scientist, intensive care, hematology & oncology. DCLLSG | Department I of Internal Medicine @UKKoeln, Germany.
Our analysis of the HD21 Older Cohort is now published in the JCO @ascocancer.bsky.social doi.org/10.1200/JCO-... @ferdinandusj.bsky.social ๐ Key take away: PET-guided 4-6x BrECADD is feasible and highly effective in older AS-cHL patients 60-75 years of age, thereby expanding treatment options ๐งต๐๐
24.07.2025 15:31 โ ๐ 2 ๐ 1 ๐ฌ 2 ๐ 0Congratulations @broeckelmann.bsky.social and @ferdinandusj.bsky.social ! Impressive effort and data to further guide treatment in older adults with Hodgkins , a much needed trial and results.
24.07.2025 16:31 โ ๐ 1 ๐ 0 ๐ฌ 0 ๐ 0
6x Nivo-AVD with PFS & OS benefit and better tolerability vs 6x BV-AVD in AS-HL pts โฅ60 years in the randomised S1826 trial. Efficacy driven by EBV status? PRO-CTCAE confirming better tolerability & revealing discrepancy to physician reporting @ascocancer.bsky.social ascopubs.org/doi/10.1200/...
17.06.2025 08:56 โ ๐ 6 ๐ 3 ๐ฌ 1 ๐ 0
A graph showing progression-free survival estimates among all participants.
Among patients with chronic lymphocytic leukemia, undetectable MRD and progression-free survival were more common with ibrutinibโvenetoclax than with ibrutinib alone or chemoimmunotherapy, with benefits sustained at 5 years. Full FLAIR phase 3 trial results: nej.md/3SMNdC4โฏโฏ
#EHA2025
Heartfelt congrats to David, Roland and the whole @uniklinikkoeln.bsky.social lymphoma team! Great to see our exciting study on targeting CSF1R+ myeloid-monocytic cells to overcome CAR-T cell resistance now published online in Cancer Cell @cp-cancercell.bsky.social: doi.org/10.1016/j.cc... ๐
13.06.2025 08:14 โ ๐ 1 ๐ 1 ๐ฌ 0 ๐ 0@thelancethaem.bsky.social @uniklinikkoeln.bsky.social
04.06.2025 17:11 โ ๐ 0 ๐ 0 ๐ฌ 0 ๐ 0Please appreciate this post by Paul on the new Beyond Maximum Grade Commission Series on AE Reporting in the Lancet Haematology.
A comprehensive update on the pivotal paper from 2018, which should inform physicians and trialists alike!
#lymsm #lymphoma #leukemia #meded
Announcing the 1st paper of โช@thelancethaem.bsky.socialโฌ Commission on Adverse Events, with Drs. @biostatgirl.bsky.socialโฌ & Thanarajasingam.
We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination.
buff.ly/SchRHhq
Thread โฌ๏ธ๐งต
Late breaking at #ASCO25:
A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial: nej.md/4mh5RPL
@ascocancer.bsky.social
Happy to share our systematic Cochrane review on vaccines for preventing infections in patients with hematological malignancies: doi.org/10.1002/1465... In light of infection-related morbidity and non-relapse mortality in our patients, this is an important issue where we lack high-quality evidence.
21.05.2025 18:57 โ ๐ 2 ๐ 1 ๐ฌ 1 ๐ 0
Apart from COVID-19โrelated adverse events, the triple combination was well tolerated. buff.ly/ARqMYrh #clinicaltrialsandobservations #lymphoidneoplasia #hemesky
26.03.2025 16:06 โ ๐ 3 ๐ 1 ๐ฌ 0 ๐ 0
Honored to write a Commentary in @natrevclinoncol.bsky.social on recent progress, unmet needs and future perspectives in Hodgkin lymphoma: rdcu.be/ecWQh: "The positive results of HD21 & S1826 should not curb but rather spark further practice-changing research for the benefit of all patients with HL"
10.03.2025 19:19 โ ๐ 6 ๐ 2 ๐ฌ 0 ๐ 1
A Lancet Editorial: โAmerican chaos: standing up for health and medicineโ
โ...to care is an act not of weakness, but of strength.โ
The Lancet response: bit.ly/4jRb5Av
LAST CHANCE to register & join us for our Post-ASH 2024 #CLL Highlights Webinar taking place TOMORROW๐ฉธ
Presentations & discussions on selected abstracts from #ASH24
Prof. Barbara Eichhorst, Dr Matthew Davids & Dr Kerry Rogers
๐https://buff.ly/4hSDgxY
#CLLsm #LeuSM
Comprehensive interdisciplinary review on current and emerging therapeutic targets to treat immune-related adverse events (irAE). A rapidly evolving field of high clinical relevance elegantly summarized by Jessica Hassel and colleagues @dkfz.bsky.social @cellpress.bsky.social doi.org/10.1016/j.it...
30.12.2024 08:08 โ ๐ 5 ๐ 3 ๐ฌ 1 ๐ 0
